Prognosis and management of membraneous nephropathy.
dc.contributor.author | Pahari, D K | en_US |
dc.contributor.author | Das, S | en_US |
dc.contributor.author | Dutta, B N | en_US |
dc.contributor.author | Banerjee, D | en_US |
dc.date.accessioned | 1993-06-01 | en_US |
dc.date.accessioned | 2009-05-31T05:06:35Z | |
dc.date.available | 1993-06-01 | en_US |
dc.date.available | 2009-05-31T05:06:35Z | |
dc.date.issued | 1993-06-01 | en_US |
dc.description.abstract | Patients of idiopathic membranous nephropathy (MGN) were randomly assigned to received steroid and cyclophosphamide every other month (Gr-I) and steroid alone (Gr-II). Of 36 patients in Gr.I, 33 patients achieved complete remissions, 2 had relapsing course with remission on further courses of therapy and only one has reached end stage renal failure. In contrast, of the 35 patients in Gr. II, 15 (P < 0.001) achieved complete remission, 7 are in partial remission, 5 have no response, another 5 have deterioration of renal function of which two required dialysis, and 3 have relapsing course after the initial remission. Mean follow up period was 46 +/- 10.2 months. We conclude that steroid and cyclophosphamide every other month is highly effective in achieving remission in patients with membranous nephropathy. | en_US |
dc.description.affiliation | Department of Medicine, Institute of Post Graduate Medical Education & Research, Calcutta. | en_US |
dc.identifier.citation | Pahari DK, Das S, Dutta BN, Banerjee D. Prognosis and management of membraneous nephropathy. Journal of the Association of Physicians of India. 1993 Jun; 41(6): 350-1 | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/95307 | |
dc.language.iso | eng | en_US |
dc.source.uri | https://www.japi.org | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Cyclophosphamide --administration & dosage | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Drug Administration Schedule | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-Up Studies | en_US |
dc.subject.mesh | Glomerulonephritis, Membranous --drug therapy | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Prednisolone --administration & dosage | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.title | Prognosis and management of membraneous nephropathy. | en_US |
dc.type | Clinical Trial | en_US |
dc.type | Comparative Study | en_US |
dc.type | Journal Article | en_US |
dc.type | Randomized Controlled Trial | en_US |
Files
License bundle
1 - 1 of 1